Oxamniquine in the treatment of various schistosome infections in South Africa.

Trials of a new schistosomicide oxamniquine (Vansil) were carried out in the lowveld of the Eastern Transvaal. After initial dose-finding trials, the safety and efficacy of oxamniquine against Schistosoma mansoni at an oral dose of 15 mg/kg twice a day for 2 days (total dose 60 mg/kg), were confirmed. No detectable effect was noted against S. haematobium or S. mattheei.